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ABSTRACT 
Introduction: It is unclear whether maternal supplementation with small-quantity lipid-based 
nutrient supplements (SQ-LNS,118 kcal/d) would affect maternal weight. 
Objective: We compared several secondary anthropometric measures among 3 groups of women 
in the iLiNS-DYAD trial in Ghana. 
Methods: Women (n=1320; <20 weeks’ gestation) were randomly assigned to receive 60 mg Fe 
+ 400 μg folic acid/d (IFA), 18 vitamins and minerals/d (MMN), or 20 g/d SQ-LNS with 22 
micronutrients (LNS) during pregnancy, and placebo (200 mg Ca/d), MMN or SQ-LNS, 
respectively, during 6 mo postpartum. Weight, mid upper-arm circumference (MUAC), and 
triceps skinfold (TSF) thickness at 36 weeks’ gestation and 6 mo postpartum were analyzed, as 
well as changes from estimated pre-pregnancy values. We assessed the adequacy of estimated 
gestational weight gain (GWG) by using Institute of Medicine (IOM) and INTERGROWTH-21st 
guidelines. 
Results: Estimated pre-pregnancy prevalence of overweight or obesity was 38.5%. By 36 weeks’ 
gestation, women (n=1015) had a mean ± SD weight gain of 7.4 ± 3.7 kg, and changes of -1.0 ± 
1.7 cm in MUAC and -2.8 ± 4.1 mm in TSF. The LNS group had a lower prevalence of 
inadequate GWG based on IOM guidelines (57.4%) than the MMN (67.2%) but not the IFA 
(63.1%) groups (P = 0.030), whereas the prevalence of adequate (26.9% overall) and excessive 
(10.4% overall) GWG did not differ by group. The percentage of normal weight 
(18.5<BMI<25.0) women (n=754) whose GWG was <3rd centile of the INTERGROWTH-21ST 
Standards was 23.0%, 28.7% and 28.5% for the LNS, MMN, and IFA groups, respectively 
(P=0.36). At 6 mo postpartum, the prevalence of overweight or obesity was 45.3%, and the risk 
of becoming overweight or obese did not differ by group.  
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Conclusion: SQ-LNS supplementation is one potential strategy to address the high prevalence of 
inadequate GWG in similar settings, without increasing the risk of excessive GWG. 
Clinicaltrials.gov identifier: NCT00970866. 
Keywords:  gestational weight gain; lipid-based nutrient supplements; maternal 
supplementation; multiple micronutrient supplementation; iron + folic acid 
supplementation. 
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Introduction 
In many developing counties, pregnant and/or lactating women often suffer from vitamin 
and mineral deficiencies (1) commonly as a result of poor diet (2, 3), and the amounts of 
essential fatty acids available from the food supply may be below the minimum recommended 
level for pregnant and lactating women (4). Vitamin and mineral deficiencies during pregnancy 
contribute to intrauterine growth retardation and pregnancy-related and delivery complications 
(5), and therefore efforts to combat these deficiencies are a global priority (6).  
Iron + folic acid supplementation (7) has been the main nutritional supplementation 
regimen for pregnant women in low income countries for decades, and has been found to reduce 
the risk of maternal anemia (8, 9) and iron deficiency (9) when compared with no iron or 
placebo. However, evidence from a recent Cochrane Review (10) suggests that multiple-
micronutrient supplementation for pregnant women may be superior to iron supplementation 
with or without folic acid in terms of reducing the incidence of low birthweight (LBW), small-
for-gestational-age (SGA), and stillbirth delivery.  
Small-quantity lipid-based nutrient supplements (SQ-LNS) providing 22 vitamins and 
minerals, including minerals not usually incorporated in multiple micronutrient supplements, 
offer a relatively new strategy for delivering not only multiple micronutrients, but also essential 
fatty acids to pregnant and lactating women. Published evidence from our study in Ghana (11) 
and another study from Bangladesh (12) showed a positive impact of pre-natal SQ-LNS 
supplementation on fetal growth, particularly among women at a greater risk of delivering 
infants with intra-uterine growth retardation. Given these results, interest in the use of maternal 
SQ-LNS supplementation in low income communities might grow.  
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The Institute of Medicine (IOM) provides recommendations about gestational weight 
gain (GWG) based on pre-pregnancy body mass index (BMI): underweight women have the 
greatest recommended weight gain range (12.5-18 kg), followed by normal weight (11.5-16 kg), 
then overweight (7-11.5 kg) and obese (5-9 kg) women (13). More recently, the 
INTERGROWTH-21st Project published GWG standards by using data from more diverse 
populations compared to the IOM’s recommendations (14). However, unlike the IOM 
recommendations, the INTERGROWTH-21st Standards are appropriate for normal weight 
women only, and therefore the former recommendations may have a greater applicability. 
Deviations from GWG recommendations have been associated with adverse 
consequences for both the mother and child: inadequate GWG is associated with increased risk 
of low birth weight, whilst excessive GWG is associated with infant macrosomia and maternal 
postpartum weight retention and development of overweight or obesity (13). Prolonged 
consumption of SQ-LNS during pregnancy and lactation may affect women’s weight, but so far, 
only one study in Bangladesh (15) has examined this relationship. 
In this analysis, we examined several secondary outcomes of our iLiNS-DYAD efficacy 
trial in Ghana (11), a RCT carried out by the International Lipid-based Nutrient Supplement 
study group in which mother-child dyads were enrolled. We aimed to determine whether the 
consumption of SQ-LNS was associated with differences in GWG or maternal anthropometric 
characteristics, including risk of overweight or obesity, when provided during pregnancy and the 
first 6 mo postpartum in a semi-urban setting in Ghana, where energy intake among women is 
generally not limiting and overweight and obesity are matters of growing concern.  
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Methods 
Study setting, design, and participants 
We have previously described the setting, design and participants of the iLiNS-DYAD 
efficacy trial in Ghana (11). Briefly, the study was conducted in a semi-urban settlement 
(Somanya-Odumase-Kpong area) in the Yilo Krobo and the Lower Manya Krobo districts about 
70 km north of Accra, Ghana. It was designed as a parallel, individually randomized, controlled 
trial with three equal-size groups. The study protocol was approved by the ethics committees of 
the University of California, Davis; the Ghana Health Service; and the University of Ghana 
Noguchi Memorial Institute for Medical Research, and was registered at ClinicalTrials.org 
(Identifier NCT00970866). 
Participants were pregnant women attending usual antenatal clinics in the 4 main health 
facilities in the area between December 2009 and December 2011, who were ≥18 years old; ≤20-
weeks gestation; and had antenatal cards complete with history and examination. A woman was 
excluded if any of the following applied: not residing in the area; intention to move out of the 
area within the next two years; milk or peanut allergy; unwillingness to receive field workers or 
take study supplement; participation in another trial; gestational age (GA) >20 weeks before 
completion of enrolment; and antenatal card indicated HIV infection, asthma, epilepsy, 
tuberculosis, or malignant disease.  
Intervention 
We described previously (11) that following baseline assessments, eligible women were 
randomized to receive one of 3 treatments: (a) 60 mg iron plus 400 μg folic acid/d during 
pregnancy, and placebo (200 mg Ca/d)  during the first 6 mo postpartum (hereafter, IFA 
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supplement or group); (b) multiple micronutrient capsule containing 18 vitamins and minerals 
(including 20 mg iron)/d during pregnancy and the first 6 mo postpartum, (hereafter, MMN 
supplement or group); and (c) 20 g/d of SQ-LNS containing similar micronutrients as the MMN 
supplement, plus Ca, P, K, and Mg as well as energy (118 kcal/d) and macronutrients (e.g. 
protein and essential fatty acids) during pregnancy and the first 6 mo postpartum (hereafter, SQ-
LNS supplement or LNS group). The LNS (individual 20-g sachets) was supplied by Nutriset 
S.A.S. (Malaunay, France), and the IFA and MMN (10 capsules/blister pack) by DSM South 
Africa. We previously published the nutrient contents of all supplements (11), and the rationale 
for the concentrations of the nutrients (16).   
Apart from iron, the vitamin and mineral contents of the MMN and SQ-LNS supplements 
were either 1x or 2x the recommended dietary allowance for pregnancy, or in a few cases, the 
maximum amount that could be included in the supplement given technical and organoleptic 
constraints (16). Group allocations were developed by the Study Statistician using a computer-
generated (SAS version 9.4) scheme in blocks of nine, and randomization was performed by the 
Study Nurse who offered 9 sealed, opaque envelopes at a time, one of which was picked by the 
participant to reveal the allocation. Allocation information was kept securely by one Field 
Supervisor and the Study Statistician only.  
At enrolment, the study nurse gave each woman a two-week supply of the assigned 
supplement with instructions on how to consume it (IFA and MMN, with water after a meal, one 
capsule per day; SQ-LNS, mixed with any prepared food, one 20-g sachet per day), and a 
standard nutrition message (“Do not forget to eat meat, fish, eggs, fruits, and vegetables 
whenever you can; you still need these foods even as you take the supplement we have given 
you”) designed to reflect Ghana Health Service’s nutritional advice for women during pregnancy 
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(17) and local food availability. Thereafter, field workers visited women in their homes 
biweekly, whereupon they delivered fresh supplies of supplement and monitored supplement 
intakes and monitored morbidity (11).  
After birth, field workers visited women and their infants each week, but the delivery of 
supplement and monitoring of intakes and morbidity were done biweekly as before, until women 
exited at 6 mo postpartum.  During follow-up, women were told not to consume more than one 
capsule (IFA and MMN groups) or sachet (LNS group) per day, even if they forgot to take the 
supplement the previous day or days. Women were told to take their assigned supplement with 
them if they wanted to travel out of the study area. Those who would not return before the next 
biweekly visit were given an extra supply for the period they intended to be away.     
To maintain blinding, the IFA and MMN supplements were color-coded (3 different 
colors for IFA and 3 for MMN supplements), and were therefore known to the study team and 
participants only by the colors. It was not possible to blind field workers and participants to the 
IFA and MMN supplements versus the SQ-LNS supplement due to their apparent differences, 
but the anthropometrists who measured the women were blinded to the group assignments, and 
no one apart from the Study Statistician had knowledge of group assignment until all preliminary 
analyses had been completed. 
Outcome measures and procedures 
The outcome measures evaluated at 36 weeks’ gestation (last laboratory visit before 
delivery) were: total gestational weight (kg), mid-upper circumference (MUAC, cm) and triceps 
skinfold (TSF, mm) gain; GWG per week; percentage adequacy of GWG achieved; percentage 
of women whose GWG was inadequate (< lower cut-off of recommendations), adequate (within 
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recommended range) or excessive (> upper cut-off of recommendations) according to the IOM 
GWG recommendations (13); and the percentage of normal weight (18.5<BMI<25.0) women 
whose estimated GWG was <3rd centile or >97th centile of the INTERGROWTH-21ST Standards 
(14) . Outcomes evaluated at 6 mo postpartum (maternal endpoint of the study) were weight, 
MUAC, TSF, and BMI (kg/m2); change in weight, MUAC, TSF, and BMI from pre-pregnancy; 
and percentage of women who became overweight or obese out of those who were not 
overweight or obese at pre-pregnancy.  
We collected background demographic and socio-economic information at enrolment by 
using a questionnaire, and completed anthropometric and laboratory assessments at enrolment, 
36 weeks gestation, and 6 mo postpartum. Weight (Seca 874; Seca), height (Seca 217; Seca), 
mid-upper arm circumference, and triceps skinfold (Holtain calipers) were measured using 
standard procedures. Blood hemoglobin concentration was measured by HemoCue (HemoCue 
AG, Switzerland), and malaria parasitemia was by a kit (Vision Biotech, South Africa) (11). As 
described previously (11), gestational age was determined mostly by ultrasound biometry (Aloka 
SSD 500, Japan).  
Sample size and data analysis 
The sample size for the iLiNS-DYAD-Ghana study (11) was based on detecting a small-
to-moderate (18) effect size (Cohen’s d) of 0.3 between any two groups for any continuous 
outcome measure, with a two-sided 5% test and 80% power. As previously reported (11), a total 
of 1320 pregnant women were enrolled into the study. We also previously reported (11) a 
temporary mislabeling of IFA and MMN capsules, as a result of which 170 women who had 
been assigned to the IFA group inadvertently received the MMN capsule either throughout 
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pregnancy (n=85) or during part of pregnancy (n=85), before receiving the intended IFA capsule 
the rest of follow-up, and another 170 women assigned to the MMN group also received the IFA 
capsule either throughout pregnancy (n=78) or during part of pregnancy (n=92), before receiving 
the intended MMN capsule. In this current analysis which covered both pre- and post-natal 
periods of the intervention, we included all of the women enrolled into the study without 
discarding any data from those who received the unintended supplements, since the unintended 
exposure occurred only in the pre-natal period. We used this same approach in our previous 
publication (19) in which we evaluated the impact of the intervention spanning pre- and post-
natal periods on the attained growth of 18-mo-old children. We estimated that the actual 
percentage of follow-up days (13%) during which the women in the IFA and MMN groups had 
the unintended exposure was relatively small (19), and in addition, no women in the LNS group 
were exposed to any other supplement apart from the intended SQ-LNS. At 36 weeks gestation 
and 6 mo postpartum, we had anthropometric data for 1,015 and 1,073 women, respectively. 
With these sample sizes, we had >97% power to detect an effect size of 0.3 between any two 
groups for any continuous outcome at each of the time points.  
We developed our statistical analysis plan (SAP) and posted it at our web-site 
(www.ilins.org) before data analysis. The secondary outcomes in the present analysis were pre-
specified in the SAP. Statistical analysis was performed on an intention-to-treat basis using 
SAS for Windows Release 9.4 (Cary, NC, USA). Thus, women were included in the analysis 
regardless of adherence to treatment. To address the protocol violation as a result of the 
consumption of mislabeled capsules by some women during pregnancy, we analyzed the data 
using 2 scenarios as done previously (19): in the first, intervention groups were based on the 
supplement women were intended to receive when they were enrolled, and in the second, 
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intervention groups were based on the supplement women actually received when they were 
enrolled.  
The variables used to assess the outcome measures were obtained as follows: first, 
because it was not possible to obtain women’s pre-pregnancy weight (needed to apply the IOM 
GWG recommendations), we used a third-degree polynomial regression model with one 
predictor variable (gestational age at enrolment) to estimate pre-pregnancy weight based on 
weight and gestational age at the time of enrolment. In this case, the shape of the true non-linear 
response function of maternal weight to gestational age was unknown (or complex), and a 
polynomial function was a good approximation to the true function (20). The procedure was 
accomplished, first, by determining the best transformation of the weight at enrolment that 
achieved a normal distribution, and regressing the transformed weight on gestational age, 
gestational age squared, and gestational age cubed in order to generate predicted and residual 
values. We then inspected the regression curve to determine the earliest gestational age before 
the confidence interval expanded, assuming that weight gain before that time was minimal. Next, 
we determined the mean of the predicted values at the selected time point in early gestation, 
added this mean value to the residual for each individual, and then back-transformed the result to 
obtain the estimated pre-pregnancy weight for the individual. We used the same approach to 
estimate the pre-pregnancy MUAC and TSF based on the values measured at enrolment. We 
estimated pre-pregnancy BMI (kg/m2) as estimated pre-pregnancy weight divided by the square 
of height measured at the time of enrolment. 
We calculated the total GWG, gestational MUAC gain and gestational TSF gain by 
subtracting the estimated pre-pregnancy values from those measured at the last prenatal visit to 
the laboratory around 36 weeks gestation, an approach used by other investigators (21). The rate 
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of GWG by 36 gestational weeks was calculated as total GWG divided by completed weeks of 
gestation (22). The percentage adequacy of GWG as a continuous variable was calculated by 
dividing the total GWG by the expected GWG (i.e the amount of weight a woman was supposed 
to gain according to the IOM recommendation when her weight was measured around 36 weeks 
gestation ) and multiplying the result by 100 (21). For the expected GWG, we used the formula: 
Expected GWG = Expected 1st trimester total weight gain + [(Gestational age at the last weight 
measurement around 36 weeks’ gestation – 13 weeks) x Recommended rate of GWG for 2nd and 
3rd trimesters] (21, 23, 24). Expected first-trimester total weight gain was assumed to be 2 kg for 
underweight and normal-weight women, 1 kg for overweight women, and 0.5 kg for obese 
women (21), and the recommended rates of GWG for 2nd and 3rd trimesters were 0.5, 0.4, 0.3, 
and 0.23 kg/week for underweight, normal weight, overweight, and obese women, respectively 
(25).  
Because the IOM recommends a range of total GWG for each pre-pregnancy BMI group, 
we classified the percentage of weight-gain recommendations met as inadequate, adequate, or 
excessive (26). For each BMI-specific range, we divided the lower and upper limits of the 
recommended weight-gain range by the expected weight gain by 40 weeks’ gestation and 
multiplied the result by 100 to obtain the corresponding range of recommended percentage of 
expected weight gain (26). For example, for women with normal pre-pregnancy BMI, the 
expected gestational weight gain by 40 weeks’ gestation is: 2.0 kg + [(40 weeks – 13 weeks) x 
0.4 kg/week] = 12.8 kg. For the IOM’s recommended total weight-gain range of 11.5–16 kg, the 
lower and upper limits of the corresponding range of the recommended percentage of expected 
weight gain are: 11.5 kg/12.8 kg x 100 and 16 kg/12.8 kg x 100 = 90% – 125% of the 12.8 kg 
expected weight gain. Hence we classified inadequate, adequate and excessive weight gain as 
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<90%, 90–125% and >125% of recommendations, respectively. For a normal-weight woman 
who gained a total of 9.0 kg and whose weight was last measured at 37 weeks’ gestation, the 
expected GWG would be 11.7 kg, and the percentage of recommendations met would be 9.0 
kg/11.7 kg x 100= 77%, which would be classified as inadequate GWG. Changes in weight, 
MUAC, TSF, and BMI from pre-pregnancy to 6 months postpartum were calculated by 
subtracting the estimated pre-pregnancy values, from the values measured at 6 months 
postpartum. 
To examine how the GWG assessment using the IOM’s recommendation would compare 
with similar assessment using the INTERGROWTH-21st Standards, we calculated the 3rd and the 
97th centiles of expected GWG at the last antenatal measurement around 36 weeks’ gestation. For 
the 3rd centile GWG, we used the formula:  
exp({1.382972 - 56.14743 * GA**-2 + 0.2787683 * GA **0.5} + {-1.88 * [0.2501993731 + 
142.4297879 * GA **-2 - 61.45345 * GA **-2 * log(GA)]}) - 8.75,0.1), where GA = weeks of 
gestation at the last antenatal measurement (14). For the 97th GWG, we replaced the -1.88 in the 
formula for the 3rd centile of expected GWG by 1.88 (14). We used actual GWG less than the 
calculated 3rd centile of the expected GWG as a proxy for inadequate GWG, and actual GWG 
greater than the calculated 97th centile of expected GWG as a proxy for excessive GWG. 
Because the INTERGROWTH-21st Standards are appropriate for normal weight women, only 
women in our sample who had estimated pre-pregnancy BMI between 18.5 and 24.99 kgm-2 
were included in the analysis involving those standards. 
We summarized the background characteristics at enrolment (11), and the number of 
days from the last prenatal measurements (around 36 weeks’ gestation) to delivery as mean ± SD 
or frequency (%) using the group assignment based on supplements women were intended to 
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receive when they were enrolled. At 36 weeks’ gestation and 6 mo postpartum, we calculated 
descriptive statistics for the overall sample, before comparing the 3 treatment groups using 
general linear models (continuous outcomes) and logistic regression models (binary), with 
Tukey-Kramer adjustment for multiple comparisons. Along with the group comparisons, we 
calculated pairwise mean differences (continuous outcomes) and relative risks (binary outcomes) 
with their 95% CI and p-values. Relative risks were calculated using Poisson regression  (27).  
These comparisons were performed twice, first without any covariate adjustments, and then with 
adjustment for covariates significantly associated (p<0.10) with the outcome in question in a 
bivariate analysis. Potential covariates were specified before analysis, and included primiparity 
(yes/no), season at enrolment (wet/not wet), anemia (yes/no), age, gestational age at enrolment, 
and assets index, housing index, and Household Food Insecurity Access Scale (HFIAS) score 
derived using principal  component analysis (28). Finally, as done previously (19) as a possible 
option for addressing the protocol violation, we performed a secondary analysis of the outcome 
variables, in which we combined women in the IFA and MMN groups to conduct a 2-group 
comparison with those who consumed the SQ-LNS. We considered that for these assessments in 
a clinical trial, in which all of the outcomes were secondary, pre-specified, and highly correlated, 
correcting for multiplicity was unnecessary (29).  
Statistics in the texts are means ± SD (continuous outcomes) or percentages (binary 
outcomes). Women’s adherence to supplement intake, defined as the percentage of follow-up 
days women self-reported consuming the supplements (pregnancy/lactation) was: 88.1%/85.7 % 
for the IFA group; 87.0 %/85.0 % for the MMN group; and 83.7 %/80.0 % for the LNS group, as 
reported previously (30). Data on morbidity have yet to be analyzed, but we reported previously 
(11, 19) that serious adverse events were evenly distributed across the 3 groups.  




The characteristics of the women enrolled, by intervention group, are shown in Table 1: 
on average, the women were aged about 27 y, had 8 y of education, were generally not food 
insecure, and had a relatively low estimated rate of underweight (3.1%) and a high estimated rate 
of overweight and obesity (38.5%)  at pre-pregnancy. These characteristics were generally 
balanced across the 3 groups.  Number of days from the last prenatal measurement to delivery 
was 21.8 ± 10.5.  
Based on the estimated pre-pregnancy values, the overall GWG at 36 weeks’ gestation 
was 7.4 ± 3.7 kg, which was equivalent to 0.2 ± 0.1 kg per week, and 76.8 ± 43.0% of the 
expected weight gain according to the IOM’s weight-gain recommendation.  Women lost 1.0 ± 
1.7 cm in MUAC and 2.8 ± 4.1 mm in TSF. The percentages of women in the sample who had 
inadequate, adequate and excessive GWG at 36 weeks gestation by the IOM recommendations 
were 62.7%, 26.9% and 10.4%, respectively. On average, 26.8% of women with estimated 
normal BMI at pre-pregnancy had total GWG <3rd centile of the expected GWG based on the 
INTERGROWTH-21st Standards, but none had total GWG above the 97th centile of the expected 
GWG based on the INTERGROWTH-21st Standards.  
By 6 mo postpartum, the overall mean ± SD (median) changes in women’s 
anthropometric indices from the estimated pre-pregnancy values were +1.6 ± 4.9 (1.5) kg for 
weight, +0.4 ± 2.0 (0.3) cm for MUAC, +0.6 ± 5.0 (0.3) mm for TSF, and +0.6 ± 1.9 (0.5) kg/m2 
for BMI. The overall prevalence of underweight (BMI <18.5 kg/m2) remained relatively low 
(3.7%), whereas 45.3% of the women were overweight or obese. 
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Group comparisons 
The unadjusted results for the continuous outcome measures for the analysis based on 
groups according to the supplements women were intended to receive at enrolment are presented 
in Table 2. At 36 weeks’ gestation and 6 mo postpartum, the 3 groups did not differ in the 
unadjusted mean values of the continuous outcome measures, except for a tendency towards a 
greater percent adequacy of GWG in the LNS group compared to the other groups (Overall P = 
0.09). In adjusted analysis controlling for covariates significantly associated with the outcome in 
question (details not shown), there were trends towards greater mean total estimated GWG 
(Overall P = 0.07), GWG per week (Overall P = 0.07) and percent adequacy of GWG (P = 0.08) 
for women in the LNS group compared to those in the other groups. Similar results for both 
unadjusted (Supplemental Table 1) and adjusted (table not shown) analyses were generally 
observed when groups were examined according to the supplements women actually received 
when they were enrolled. 
When comparing women in the IFA and MMN groups combined versus those in the LNS 
group (Supplemental Table 2), the trends towards greater mean total GWG (P = 0.08) and 
GWG per week (P = 0.09) for the LNS group paralleled those observed in the 3-group 
comparison, and mean ± SD percent adequacy of GWG in the LNS group was significantly 
greater (P = 0.038) than that for the combined IFA + MMN group.  
The unadjusted results for the binary outcome measures for the analysis examining 
groups according to the supplements women were intended to receive at enrolment are presented 
in Table 3. At 36 weeks gestation, the 3 groups did not differ significantly in the percentage of 
women with adequate or excessive GWG according to the IOM’s recommendations, but the 
percentage of women who had inadequate GWG was significantly lower in the LNS (57.4%) 
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compared to the MMN (and not the IFA) group (67.2%; Overall P = 0.030 corresponding to RR 
= 0.85 [95% CI: 0.74, 0.98; P = 0.023]). Among women with estimated normal BMI at pre-
pregnancy, the point estimate of the percentage of those whose total GWG was <3rd centile of the 
expected GWG based on the INTERGROWTH-21st Standards was 23% for the LNS group, 
compared to 28.5% for the IFA group, and 28.7% in the MMN group, although the differences 
were not significant. The percentage of women with normal BMI at pre-pregnancy who became 
overweight or obese by 6 mo postpartum also did not differ significantly among the 3 groups. 
These results remained unchanged after controlling for pre-specified covariates significantly 
associated with the outcomes (details not shown). As observed for the continuous outcome 
variables, similar results for the binary outcome variables were found in the analysis based on the 
supplements women actually received when they were enrolled (unadjusted, Supplemental 
Table 3; adjusted, table not shown).  
In the 2-group comparison (Supplemental Table 4), the percentage of women with 
inadequate GWG was significantly lower (P = 0.016), and the percentage of women with 
adequate GWG was significantly greater (P = 0.038) in the LNS group compared to the IFA and 
MMN groups combined. Also, the results from the analysis using the INTERGROWTH-21st 
Standards mimicked those for the three-group comparison.         
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Discussion 
In the semi-urban setting in Ghana where the iLiNS DYAD study was conducted, we 
found that at 36 weeks’ gestation, women in the LNS, MMN and IFA groups did not differ 
significantly in most of the secondary anthropometric (weight, MUAC and TSF) outcomes 
measured. However, by IOM recommendations, the prevalence of inadequate GWG based on 
estimated pre-pregnancy values was significantly lower in the LNS group compared to the MMN 
group, and in a 2-group analysis, mean ± SD percent adequacy of GWG was significantly 
greater, the prevalence of inadequate GWG was significantly lower, and the prevalence of 
adequate GWG was significantly greater in the LNS group than the non-LNS group (IFA and 
MMN groups combined). At 6 mo postpartum, the groups did not differ in weight, MUAC, TSF, 
BMI or changes in these indices from estimated pre-pregnancy values, nor in the percentage of 
women with excessive GWG, or the percentage of women who had normal BMI at pre-
pregnancy but became overweight or obese by 6 mo postpartum.  
An estimate of each woman’s pre-pregnancy BMI was a pre-requisite for applying the 
IOM’s GWG recommendations. Previously, the proxies used for pre-pregnancy weight or BMI 
have included weights measured at various times including: first antenatal booking (31), within 
the previous 12 months of pregnancy (32), in the first trimester (33, 34) and during pregnancy 
regardless of gestational age (35). As previously noted (36), each of these has its own limitations. 
We considered our approach to estimate pre-pregnancy weight or BMI (and also MUAC and 
TSF) using polynomial regression (20, 37, 38) as a good option, for 2 reasons: first, women in 
this population usually do not know their pre-pregnancy weight. Second, at a mean gestational 
age of 16.1 wk when women were enrolled, the estimated pre-pregnancy weight of 61.9 ± 11.9 
kg implied that the women on average had potentially gained 0.7 kg in weight by the time of 
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enrollment, and we decided not to ignore this change, as well as those in MUAC and TSF 
thickness that had occurred. The IOM assumes that women gain 0.5 – 2.0 kg during the first 
trimester (13), and therefore the average estimated 0.7 kg gain by the time of enrolment would be 
considered reasonably unbiased. 
The estimated pre-pregnancy BMI for women in our study, who were aged 18-45 y, was 
similar to the mean BMI (24.8 kg/m2) reported for women 15-49 y of age (excluding those who 
were pregnant, or had given birth the previous 2 mo) in the 2014 Ghana Demographic and 
Health Survey (39) for the region of Ghana (Eastern Region) where our study was conducted.  
Thus, we believe the estimation of pre-pregnancy weight, MUAC and TSF did not generally bias 
our results. 
The losses in MUAC and TSF in the sample at 36 weeks’ gestation compared to 
estimated pre-pregnancy values appear to be characteristic to pregnancy, during which fat is 
mobilized from the upper body and preferentially deposited over the hips, back, and upper thighs 
(13, 40). Our results showing the estimated prevalence of inadequate GWG according to IOM 
recommendation (63%) and percentage of normal weight women whose estimated GWG was 
less the 3rd centile of expected GWG according to the INTERGROWTH-21st Standards (27%) 
suggest that low GWG might be a problem in this setting. This observation is consistent with the 
area being located in the Eastern Region, which has the highest prevalence of low birth weight 
(14%) among the 10 regions of Ghana (39). Low GWG is associated with low birth weight (41). 
Elsewhere in Ghana, a low GWG prevalence of 50% based on the IOM’s guidelines was 
reported. Thus, SQ-LNS supplementation during pregnancy might help, albeit modestly, to 
reduce low GWG in this setting.   
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   Two previous reports may be relevant in relation to our results. In a large cluster-
randomized trial in Bangladesh in which women received iron + folic acid or SQ-LNS with 
similar nutrient content to those provided in this study (15), the provision of SQ-LNS increased 
maternal weight gain and MUAC only in certain subgroups (for example, women ≥ 25 y of age) 
but, as in Ghana, it was not associated with excessive GWG. In a Cochrane Review (42), 
balanced protein-energy supplements (i.e., supplements in which protein provides less than 25% 
of the total energy content) given to pregnant women increased mean weight gain per week 
compared to no supplementation, but the daily amounts of energy in those supplements  were 
substantially larger (> 400 kcal) than the amount present in SQ-LNS (118 kcal).  
 Our finding that SQ-LNS supplementation decreased the prevalence of inadequate GWG 
but was not associated with excessive GWG or risk of overweight and obesity at 6 mo 
postpartum implies a favorable response to using SQ-LNS, particularly for populations such as 
that of the study setting where the nutrition transition is underway. The high prevalence of 
inadequate GWG observed in this cohort, coupled with the 12% prevalence of low birth weight 
that we previously reported (11), suggest that low energy intake during pregnancy may be an 
issue of concern in this population, even though a substantial percentage of the women were 
overweight prior to pregnancy. Low energy intake and low intake of dairy products have been 
identified as important predictors of inadequate GWG (43-45), along with other biological or 
metabolic factors (27). SQ-LNS provided a small amount of extra energy, and milk powder was 
one of the ingredients, which may have contributed to the reduced prevalence of inadequate 
GWG in the LNS group. The results reported herein are consistent with the previously reported 
greater mean birth weight and lower prevalence of low birth weight of infants in the LNS group 
(11). 
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 Because the consumption of SQ-LNS was not associated with greater total gestational 
weight gain or higher prevalence of excessive gestational weight gain in our sample, it is not 
surprising that it was also not associated with a greater risk of becoming overweight or obesity 
by 6 mo postpartum. Women’s weight retention by 6 mo postpartum depends not only on dietary 
factors but also on physical activity and breastfeeding practices. In the study setting, where most 
women were relatively active (compared to those in, say, urban Accra) and nearly all women 
breastfed their infants during the first 6 mo postpartum (46), the extra energy provided by SQ-
LNS did not exacerbate the already high prevalence (estimated 38.5% at pre-pregnancy) of 
maternal overweight.  This is reassuring but we cannot be sure that this result is generalizable to 
other contexts.    
The iLiNS DYAD Ghana study had several strengths, including using a fully randomized 
design and having control groups. In addition, all anthropometrists were well-trained and 
standardized (47) every 6 mo during data collection. Study weaknesses include the inability to 
fully blind all study staff and participants to the supplementation allocation (due to the obvious 
differences between the IFA and MMN capsules versus the SQ-LNS sachets), lack of data on 
women’s pre-pregnancy weight, which then had to be estimated, and the exposure of some 
women to both IFA and MMN supplements during part of pregnancy. It is possible that some of 
our findings may be due to chance, because of multiple testing (29). However, all 
anthropometrists and data analysts were fully blinded to the group assignments until analyses 
were completed, and no women in the LNS group were exposed to any other supplement apart 
from the intended LNS. We therefore believe that the study weaknesses do not bias the finding 
of no association of SQ-LNS consumption with excessive GWG or increased risk of overweight 
or obesity by 6 mo postpartum. 
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We conclude that daily SQ-LNS supplementation is one potential strategy to address the 
high prevalence of inadequate GWG in similar settings, without increasing the risk of excessive 
GWG, or of becoming overweight or obese by 6 months postpartum.     
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TABLE 1 Characteristics of women (n = 1320) who participated in a randomized trial of IFA (pregnancy only), 
MMN (pregnancy and lactation), and LNS (pregnancy, lactation, and infancy) supplementation in a semi-urban 
setting in Ghana, by intervention group based on intended supplement at enrollment1 
Characteristics 
IFA  
(n = 441) 
MMN  
(n = 439) 
LNS  
(n = 440) 
Age, y 26.4 ± 5.6 (441) 26.9 ± 5.4 (439) 26.9 ± 5.6 (440) 
Years of formal education, y 7.8 ± 3.5 (441) 7.6 ± 3.6 (439) 7.6 ± 3.9 (440) 
Gestational age at enrolment, weeks 16.0 ± 3.3 (440) 16.2 ± 3.2 (436) 16.1 ± 3.3 (435) 
Asset index2 0.04 ± 1.03 (433)  0.06 ± 0.97 (431)  -.09 ± 1.00 (432)  
Housing index2 0.01 ± 1.00 (433) 0.01 ± 1.01 (431) -.01 ± 1.00 (432) 
HFIAS score3 2.6 ± 4.4 (434) 2.7 ± 4.3 (431) 2.6 ± 4.0 (432) 
Married or co-habiting, n/N (%) 408/441 (92.5) 411/439 (93.6) 405/440 (92.0) 
Primiparous women, n/N (%) 156/441 (35.4) 143/439 (32.6) 147/440 (33.4) 
Positive malarial RDT4, n/N (%) 37/440 (8.4) 42/439 (9.6) 54/440 (12.3) 
Hb <100 g/L, n/N (%) 57/440 (13.0) 68/439 (15.5) 60/440 (13.6) 
Weight5, kg 61.5 ± 11.6 (432) 61.5 ± 12.0 (429) 62.7 ± 12.3 (430) 
Body Mass Index6, kg/m2 24.4 ± 4.4 (432) 24.4 ± 4.3 (429) 24.8 ± 4.5 (430) 
Underweight6 (<18.5 kg/m2)  21/432 (4.9)   12/429 (2.8)  7/430 (1.6)  
Overweight6 (25.0-29.9 kg/m2) n/N (%)  113/432 (26.2) 112/429 (26.1) 129/430 (30.0) 
Obese6 (≥ 30.0 kg/m2) n/N (%)  48/432 (11.1) 46/429 (10.7) 49/430 (11.4) 
MUAC5, cm 28.4 ± 4.3 (432) 28.5 ± 4.2 (430) 28.9 ± 4.6 (430) 
Triceps skinfold5, mm 19.8 ± 7.8 (432) 20.1 ± 7.9 (429) 20.7 ± 7.9 (430) 
Days from last prenatal measurement to delivery 21.1 ± 9.9 (336) 21.7 ± 11.1 (357) 22.5 ± 10.4 (336) 
 
1 HFIAS, Household Food Insecurity Access Scale; IFA, Iron + Folic Acid; LNS, Small Quantity Lipid-based 
Nutrient Supplement; MMN, Multiple Micronutrients; MUAC, Mid Upper Arm Circumference. Unless otherwise 
indicated, these characteristics were measured at the time of enrolment. Values are mean ± SDs (n), unless 
otherwise indicated. n/N = number of participants whose response was “yes” for the variable in question/n of 
participants analyzed for the variable in question. 
2 Proxy indices for household socioeconomic status; higher values represent higher socioeconomic status.  
3 HFIAS is a proxy indicator for household food insecurity (28); higher values represent higher food insecurity. 
4 RDT, Rapid Diagnostic Test (Clearview Malarial Combo, Vision Biotech, South Africa), which detected P. 
falciparum and non-P. falciparum histidine-rich protein-2. 
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5Pre-pregnancy values estimated from those measured at enrolment by using third-order polynomial regression, with 
gestational age at enrolment as predictor variable.   
6Based on pre-pregnancy weight estimated from weight at enrolment using polynomial regression, with gestational 
age at enrolment as predictor variable. 
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TABLE 2 Unadjusted continuous anthropometric outcomes of women (n = 1320) who participated in a randomized trial of IFA (pregnancy only), 
MMN (pregnancy and lactation), and SQ-LNS (pregnancy and lactation) supplementation in a semi-urban setting in Ghana, by intervention group based 
on intended supplement at enrollment1 






P3 Comparison of 
MMN and IFA 
Comparison of LNS 
and IFA 
Comparison of LNS 
and MMN 
Difference 
(95 % CI) 
P Difference 
(95 % CI) 
P Difference 
(95 % CI) 
P 
36 weeks gestation           
    Total GWG4, kg 7.3 ± 3.9 
(331) 
7.2 ± 3.6 
(351) 
7.7 ± 3.7 
(331) 
0.18 -0.2 (-0.9, 0.5) 0.79 0.3 (-0.3, 1.0) 0.48 0.5 (-0.1, 1.2) 0.16 
           
     Rate of GWG4, kg/wk 0.2 ± 0.11 
(331) 
0.2 ± 0.10 
(351) 
0.2 ± 0.10 
(331) 
0.19 -0.0 (-0.0, 0.0) 0.76 0.0 (-0.0, 0.0) 0.51 0.0 (-0.0, 0.0) 0.16 
           
     Percent adequacy of GWG5 76.1 ± 43.6 
(331) 
73.7 ± 41.0 
(351) 
80.8 ± 44.2 
(331) 
0.09 -2.4 ( -10, 5.4) 0.75 4.7 (-3.1,  13) 0.33 7.1 (-0.6,  15) 0.08 
           
    Total MUAC change4, cm -1.1 ± 1.8 
(331) 
-1.1 ± 1.6 
(352) 
-0.9 ± 1.6 
(332) 
0.40 -0.0 (-0.3, 0.3) 0.98 0.1 (-0.2, 0.4) 0.54 0.2 (-0.1, 0.5) 0.41 
           
    Total TSF change4, mm -2.7 ± 4.2 
(331) 
-2.9 ± 3.9 
(351) 
-2.7 ± 4.1 
(332) 
0.76 -0.2 (-1.0, 0.5) 0.76 -0.0 (-0.8, 0.7) 0.99 0.2 (-0.6, 0.9) 0.84 
6 mo postpartum           
      Weight, kg 63.6 ± 12.7 
(355) 
63.0 ± 13.1 
(362) 
64.2 ± 13.2 
(356) 
0.52 -0.6 (-2.9, 1.7) 0.81 0.5 (-1.8, 2.8) 0.85 1.1 (-1.2, 3.4) 0.48 
           
     MUAC, cm 29.1 ± 4.2 
(355) 
29.0 ± 4.3 
(362) 
29.2 ± 4.6 
(356) 
0.84 -0.1 (-0.9, 0.6) 0.92 0.1 (-0.7, 0.8) 0.98 0.2 (-0.6, 1.0) 0.83 
           
     TSF, mm 20.9 ± 7. 6 
(355) 
20.8 ± 7.8 
(362) 
21.0 ± 7.8 
(356) 
0.95 -0.1 (-1.5, 1.3) 0.98 0.1 (-1.3, 1.4) 0.99 0.2 (-1.2, 1.5) 0.95 
           
     BMI, kg/m2 25.2 ± 4.7 
(355) 
25.0 ± 4.7 
(362) 
25.4 ± 4.8 
(356) 
0.67 -0.2 (-1.0, 0.7) 0.90 0.2 (-0.7, 1.0) 0.89 0.3 (-0.5, 1.2) 0.64 
           
    Weight change from pre- 1.9 ± 4.7 1.40 ± 5.1 1.4 ± 4.8 0.33 -0.5 (-1.4, 0.4) 0.39 -0.5 (-1.3, 0.4) 0.40 0.0 (-0.9, 0.9) 1.00 
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P3 Comparison of 
MMN and IFA 
Comparison of LNS 
and IFA 
Comparison of LNS 
and MMN 
Difference 
(95 % CI) 
P Difference 
(95 % CI) 
P Difference 
(95 % CI) 
P 
pregnancy6, kg (348) (356) (351) 
           
    MUAC change from pre-
pregnancy6, cm 
0.6 ± 2.0 
(348) 
0.3 ± 2.0 
(357) 
0.3 ± 2.1 
(351) 
0.12 -0.2 (-0.6, 0.1) 0.24 -0.3 (-0.6, 0.1) 0.14 -0.0 (-0.4, 0.3) 0.95 
           
    TSF change from pre-
pregnancy6, mm 
0.9 ± 4.9 
(348) 
0.5 ± 5.0 
(356) 
0.4 ± 5.0 
(351) 
0.30 -0.5 (-1.3, 0.4) 0.43 -0.5 (-1.4, 0.3) 0.33 -0.1 (-1.0, 0.8) 0.98 
           
     BMI change from pre-
pregnancy6, kg/m2 
0.7 ± 1.9 
(348) 
0.6 ± 2.0 
(356) 
0.5 ± 1.9 
(351) 
0.36 -0.2 (-0.5, 0.2) 0.45 -0.2 (-0.5, 0.2) 0.41 -0.0 (-0.4, 0.3) 1.00 
 
1BMI, Body Mass Index; GWG, Gestational Weight Gain; IFA, Iron + Folic Acid; LNS, Small Quantity Lipid-based Nutrient Supplement (SQ-LNS); MMN, 
Multiple Micronutrients group; MUAC, Mid Upper Arm Circumference; TSF, Triceps Skinfold. IFA group: women were intended to receive 60 mg Fe + 400 
mg folic acid/d during pregnancy, and placebo (200 mg Ca/d) during the first 6 mo postpartum; MMN group: women were intended to receive 18 vitamins and 
minerals (including 20 mg Fe)/d during pregnancy and the first 6 mo postpartum; LNS group: women were intended to receive 20 g/d LNS with the same 
micronutrients as the MMN group + Ca, P, K, and Mg as well as macronutrients during pregnancy and the first 6 mo postpartum. Results are based ANOVA 
(SAS PROC GLM). 
2Values are as Mean ± SD (n). Except for weight, MUAC, TSF and BMI at 6 mo postpartum, Mean and SD values are based on pre-pregnancy values estimated 
from those measured at enrolment, by using third-order polynomial regression with gestational age at enrolment as predictor variable.   
3P-values compare Mean ± SD of 3 groups, with Tukey-Kramer adjustment for pairwise comparisons. 
4Observed total gestational weight gain, and MUAC and TSF change were calculated by subtracting the estimated pre-pregnancy weight, MUAC and TSF, 
respectively from the weight, MUAC and TSF measured at the last prenatal visit (21). Estimated pre-pregnancy weight, MUAC, and triceps skinfold were 
calculated from baseline values by using third-order polynomial regression with gestational age at enrolment as predictor variable. Rate of GWG was calculated 
as total GWG at the last pre-natal measurement divided by completed weeks of gestation. 
5Percent adequacy of GWG (continuous: percentage of weight-gain recommendations met (26)) was calculated by dividing the observed total GWG by the 
expected GWG according to the Institute of Medicine’s recommended ranges (25) up to the woman’s last prenatal measurement. Expected GWG = expected 1st 
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trimester total weight gain + [(gestational age at the time of last weight measurement – 13 wk) x recommended rate of GWG for 2nd and 3rd trimesters] (21, 23, 
24).  
6Change from pre-pregnancy to 6 months postpartum was calculated by subtracting the estimated pre-pregnancy values from the values measured at 6 months 
postpartum.   
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TABLE 3 Unadjusted binary anthropometric outcomes of women (n = 1320) who participated in a randomized trial of IFA (pregnancy only), MMN (pregnancy 











P3 Comparison of 
MMN and IFA4 
Comparison of 
LNS and IFA4 
Comparison of 








           
Inadequate GWG5, % 63.1 (57.8, 68.2) 
[331] 
67.2 (62.1, 72.0) 
[351] 
57.4 (52.0, 62.6) 
[331] 
0.030 1.1 (0.9, 1.2) 0.50 0.9 (0.8, 1.1) 0.29 0.9 (0.7, 1.0) 0.023 
           
Adequate GWG6, % 25.7 (21.3, 30.7) 
[331] 
24.2 (20.0, 29.0) 
[351] 
31.1 (26.4, 36.3) 
[331] 
0.11 0.9 (0.7, 1.3) 0.90 1.2 (0.9, 1.6) 0.27 1.3 (1.0, 1.7) 0.11 
           
Excessive GWG7, % 11.2 ( 8.2, 15.1) 
[331] 
8.5 ( 6.0, 12.0) 
[351] 
11.5 ( 8.5, 15.4) 
[331] 
0.38 0.8 (0.4, 1.3) 0.48 1.0 (0.6, 1.7) 0.99 1.3 (0.8, 2.3) 0.41 
           
GWG <10th centile of expected 
GWG8, % 
28.5 (22.5, 35.4) 
[186] 
28.7 (23.0, 35.2) 
[209] 
23.0 (17.5, 29.6) 
[187] 
0.36 1.0 (0.7, 1.5) 1.00 0.8 ( 0.5, 1.2) 0.45 0.8 ( 0.5, 1.2) 0.40 
           
GWW >97th centile of expected 
GWG8, % 
0 0 0 - - - - - - - 
           
Developed overweight or obesity 
by 6 months postpartum9 
20.9 (15.8, 27.2) 
[196] 
15.7 (11.5, 21.2) 
[216] 
17.2 (12.6, 23.0) 
[204] 
0.37 0.8 (0.5, 1.2) 0.36 0.8 (0.5, 1.3) 0.60 1.1 (0.6, 1.8) 0.92 
           
Developed obesity by 6 months 
postpartum10 
0.5 ( 0.1,  3.5) 
[196] 
0.0 ( 0.0,  100) 
[216] 
0.0 ( 0.0,  100) 
[204] 
1.00 0.0 (0.0, 0.0) 1.00 0.0 (0.0, 0.0) 1.00 1.0 (0.8, 1.3) 1.00 
 
1GWG, Gestational Weight Gain; IFA, Iron + Folic Acid; LNS, Small Quantity Lipid-based Nutrient Supplement (SQ-LNS); MMN, Multiple Micronutrients. 
IFA group: women were intended to receive 60 mg Fe + 400 mg folic acid/d during pregnancy, and placebo (200 mg Ca/d) during the first 6 mo postpartum; 
MMN group: women were intended to receive 18 vitamins and minerals (including 20 mg Fe)/d during pregnancy and the first 6 mo postpartum; LNS group: 
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women were intended to receive 20 g/d LNS with the same micronutrients as the MMN group + Ca, P, K, and Mg as well as macronutrients during pregnancy 
and the first 6 mo postpartum. Results are based Logistic Regression (SAS PROC GLIMMIX).  
2Values are percentages (95% CI) [n]. Percentages (95% CIs) are based on pre-pregnancy values estimated from those measured at enrolment, by using third-
order polynomial regression with gestational age at enrolment as predictor variable. 
3P-value compares all 3groups, with Tukey-Kramer adjustment for pairwise comparisons. 
4Relative Risks, RR (95% CI) and their P-values are based on Poisson regression (27)  
5Below (<) the lower cut-off of Institute of Medicine (IOM)’s recommended range (13). 
6Within the IOM’s recommended range (13). 
7Above (>) the upper cut-off of Institute of Medicine (IOM)’s recommended range (13). 
8Based on INTERGROWTH-21st Standards for women whose estimated pre-pregnancy weight was normal (BMI 18.50-24.99). The 3rd centile of expected GWG 
was calculated as exp((1.382972 - 56.14743 * GA**-2 + 0.2787683 * GA **0.5) + (-1.88 * (0.2501993731 + 142.4297879 * GA **-2 - 61.45345 * GA **-2 * 
log(GA)))) - 8.75,0.1), where GA = weeks of gestational at the last antenatal measurement (14). The 97th centile of expected GWG was calculated by replacing 
the -1.88 in the formula for the 3rd centile of expected GWG by 1.88 (14). No woman in the entire sample had total GWG above the 97th centile of the expected 
GWG based on the INTERGROWTH-21st Standards. 
9Proportion of women with normal BMI pre-pregnancy who became overweight or obese by 6 mo postpartum.  
10Proportion of women with normal BMI pre-pregnancy who became obese by 6 mo postpartum.  
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SUPPLEMENTAL TABLE 1  
Unadjusted continuous anthropometric outcomes of women (n = 1320) who participated in a randomized trial of IFA (pregnancy only), MMN (pregnancy and 
lactation), and SQ-LNS (pregnancy and lactation) supplementation in a semi-urban setting in Ghana, by intervention group based on supplements received at 
enrollment1 






P3 Comparison of MMN 
and IFA 
Comparison of LNS 
and IFA 




P Difference (95 
% CI) 
P Difference (95 
% CI) 
P 
36 weeks gestation           
    Total GWG4, kg 7.3 ±  3.9 
[333] 
7.2 ±  3.5 
[349] 
7.7 ±  3.7 
[331] 
0.22 -0.05  
(-0.72, 0.61) 
0.98 0.40  
(-0.28, 1.08) 
0.34 0.46  
(-0.21, 1.13) 
0.25 
           
     Rate of GWG4, kg/wk 0.2 ±  0.1 
[333] 
0.2 ±  0.1 
[349] 
0.2 ±  0.1 
[331] 
0.23 -0.00  
(-0.02, 0.02) 
0.98 0.01  
(-0.01, 0.03) 
0.36 0.01  
(-0.01, 0.03) 
0.25 
           
     Percent adequacy of GWG5 75.0 ± 42.9 
[333] 
74.7 ± 41.8 
[349] 
80.8 ± 44.2 
[331] 
0.12 -0.33  
(-8.04, 7.39) 
0.99 5.80  
(-2.02, 13.6) 
0.19 6.12  
(-1.61, 13.9) 
0.15 
           
    Total MUAC change4, cm -1.0 ±  1.8 
[333] 
-1.1 ±  1.6 
[350] 
-0.9 ±  1.6 
[332] 
0.29 -0.10  
(-0.40, 0.20) 
0.70 0.10  
(-0.21, 0.40) 
0.73 0.20  
(-0.10, 0.50) 
0.26 
           
    Total TSF change4, mm -2.8 ±  4.1 
[332] 
-2.8 ±  4.0 
[350] 
-2.7 ±  4.1 
[332] 
0.96 0.03  
(-0.71, 0.76) 
1.00 0.08  
(-0.66, 0.83) 
0.96 0.06  
(-0.67, 0.79) 
0.98 
6 mo postpartum           
      Weight, kg 63.0 ± 11.8 
[355] 
63.7 ± 13.8 
[362] 
64.2 ± 13.2 
[356] 
0.50 0.64  
(-1.63, 2.91) 
0.79 1.14  
(-1.14, 3.43) 
0.47 0.50  
(-1.77, 2.78) 
0.86 
           
     MUAC, cm 29.1 ±  4.1 
[355] 
29.0 ±  4.5 
[362] 
29.2 ±  4.6 
[356] 
0.87 -0.10  
(-0.87, 0.67) 
0.95 0.08  
(-0.70, 0.85) 
0.97 0.17  
(-0.60, 0.94) 
0.86 
           
     TSF, mm 21.0 ±  7.5 
[355] 
20.7 ±  7.9 
[362] 
21.0 ±  7.8 
[356] 
0.89 -0.23  
(-1.59, 1.12) 
0.91 0.02  
(-1.34, 1.37) 
1.00 0.25  
(-1.10, 1.60) 
0.90 
           
     BMI, kg/m2 25.1 ±  4.4 
[355] 
25.1 ±  5.0 
[362] 
25.4 ±  4.8 
[356] 
0.73 0.04  
(-0.79, 0.88) 
0.99 0.26  
(-0.57, 1.10) 
0.74 0.22  
(-0.61, 1.05) 
0.81 
           
    Weight change from pre- 1.5 ±  4.9 1.8 ±  5.0 1.4 ±  4.8 0.61 0.26  0.76 -0.10  0.96 -0.36  0.60 
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P3 Comparison of MMN 
and IFA 
Comparison of LNS 
and IFA 




P Difference (95 
% CI) 
P Difference (95 
% CI) 
P 
pregnancy6, kg [348] [356] [351] (-0.61, 1.12) (-0.97, 0.77) (-1.22, 0.51) 
           
    MUAC change from pre-
pregnancy6, cm 
0.5 ±  2.0 
[348] 
0.4 ±  2.0 
[357] 
0.3 ±  2.1 
[351] 
0.41 -0.07  
(-0.42, 0.29) 
0.90 -0.20  
(-0.56, 0.16) 
0.39 -0.13  
(-0.49, 0.22) 
0.65 
           
    TSF change from pre-
pregnancy6, mm 
0.7 ±  4.7 
[347] 
0.7 ±  5.2 
[357] 
0.4 ±  5.0 
[351] 
0.64 0.06  
(-0.82, 0.94) 
0.99 -0.27  
(-1.15, 0.61) 
0.75 -0.33  
(-1.21, 0.54) 
0.65 
           
     BMI change from pre-
pregnancy6, kg/m2 
0.6 ±  1.9 
[348] 
0.7 ±  2.0 
[356] 
0.5 ±  1.9 
[351] 
0.60 0.10  
(-0.24, 0.44) 
0.78 -0.05  
(-0.39, 0.30) 




1BMI, Body Mass Index; GWG, Gestational Weight Gain; IFA, Iron + Folic Acid; LNS, Small Quantity Lipid-based Nutrient Supplement (SQ-LNS); MMN, 
Multiple Micronutrients; MUAC, Mid Upper Arm Circumference; TSF, Triceps Skinfold. IFA group: women received 60 mg Fe + 400 mg folic acid/d during 
pregnancy, and placebo (200 mg Ca/d) during the first 6 mo postpartum; MMN group: women received 18 vitamins and minerals (including 20 mg Fe)/d 
during pregnancy and the first 6 mo postpartum; LNS group: women received 20 g/d LNS with the same micronutrients as the MMN group + Ca, P, K, and 
Mg as well as macronutrients during pregnancy and the first 6 mo postpartum. Results are based ANOVA (SAS PROC GLM). 
2Values are as Mean ± SD (n). Except for weight, MUAC, TSF and BMI at 6 mo postpartum, Mean and SD values are based on pre-pregnancy values estimated 
from those measured at enrolment, by using third-order polynomial regression with gestational age at enrolment as predictor variable. 
3P-values compare Mean ± SD of 3 groups, with Tukey-Kramer adjustment for pairwise comparisons. 
4Observed total gestational weight gain, and MUAC and TSF change were calculated by subtracting the estimated pre-pregnancy weight, MUAC and TSF, 
respectively from the weight, MUAC and TSF measured at the last prenatal visit (1). Estimated pre-pregnancy weight, MUAC, and triceps skinfold were 
calculated from baseline values by using third-order polynomial regression with gestational age at enrolment as predictor variable. Rate of GWG was calculated 
as total GWG at the last pre-natal measurement divided by completed weeks of gestation. 
5Percent adequacy of GWG (continuous: percentage of weight-gain recommendations met (2)) was calculated by dividing the observed total GWG by the 
expected GWG according to the Institute of Medicine’s recommended ranges (3) up to the woman’s last prenatal measurement. Expected GWG = expected 1st 
trimester total weight gain + [(gestational age at the time of last weight measurement – 13 wk) x recommended rate of GWG for 2nd and 3rd trimesters] (1, 4, 5).  
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SUPPLEMENTAL TABLE 2  
Unadjusted continuous anthropometric outcomes of women (n=1320) who participated in randomized trial of daily 
IFA (pregnancy only), MMN (pregnancy + lactation) and SQ-LNS (pregnancy + lactation) supplementation in a semi-





P3 Mean difference 
 (95% CI) 
36 weeks gestation     
    Total GWG, kg 7.24 ± 3.70 (682) 7.67 ± 3.75 (331) 0.08 0.43 (-0.06, 0.92) 
     
     Rate of GWG, kg/wk 0.20 ± 0.10 (682) 0.21 ± 0.10 (331) 0.09 0.01 (-0.00, 0.03) 
     
     Percent adequacy of GWG 74.9 ± 42.3 (682) 80.8 ± 44.2 (331) 0.038 5.96 (0.32, 11.6) 
     
    Total MUAC change, cm -1.07 ± 1.70 (683) -0.92 ± 1.64 (332) 0.18 0.15 (-0.07, 0.37) 
     
    Total TSF change, mm -2.79 ± 4.06 (682) -2.72 ± 4.09 (332) 0.80 0.07 (-0.46, 0.60) 
     
6 mo postpartum     
     Weight, kg 63.3 ± 12.9 (717) 64.2 ± 13.2 (356) 0.33 0.82 (-0.83, 2.47) 
     
     MUAC, cm 29.1 ± 4.27 (717) 29.2 ± 4.62 (356) 0.66 0.13 (-0.43, 0.68) 
     
     TSF, mm 20.8 ± 7.69 (717) 21.0 ± 7.77 (356) 0.79 0.13 (-0.85, 1.12) 
     
     BMI, kg/m2 25.1 ± 4.71 (717) 25.4 ± 4.83 (356) 0.43 0.24 (-0.36, 0.85) 
     
    Weight change from pre-pregnancy4, kg 1.64 ± 4.94 (704) 1.41 ± 4.81 (351) 0.47 -0.23 (-0.86, 0.40) 
     
    MUAC change from pre-pregnancy4, cm 0.45 ± 1.98 (705) 0.29 ± 2.08 (351) 0.21 -0.17 (-0.42, 0.09) 
     
    TSF change from pre-pregnancy4, mm 0.69 ± 4.95 (704) 0.39 ± 4.96 (351) 0.35 -0.30 (-0.94, 0.33) 
     
     BMI change from pre-pregnancy4, kg/m2 0.64 ± 1.95 (704) 0.54 ± 1.89 (351) 0.45 -0.10 (-0.34, 0.15) 
 
1BMI, Body Mass Index; GWG, Gestational weight gain; IFA, Iron + folic acid; LNS, Lipid-based nutrient 
supplement; MMN, Multiple micronutrients; MUAC, Mid upper arm circumference; SQ-LNS, Small quantity lipid-
based nutrient supplement; TSF, triceps skinfold. IFA+MMN = IFA and MMN groups combined: women were 
intended to receive 60 mg iron + 400 µg folic acid during pregnancy and placebo during the first 6 mo postpartum, or  
a multiple micronutrient capsule containing 18 vitamins and minerals (including 20 mg iron) during pregnancy and the 
first 6 mo postpartum; LNS group: women received SQ-LNS-for-women with the same micronutrients as the multiple 
micronutrients, plus 4 more minerals (Ca, P, K and Mg) as well as macronutrients during pregnancy and the first 6 mo 
postpartum. All supplements were intended for daily consumption. Results are based ANOVA (SAS PROC GLM). .  
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 2Values are Mean ± SD (n). Except for weight, MUAC, TSF and BMI at 6 mo postpartum, Mean and SD values are 
based on pre-pregnancy values estimated from those measured at enrolment, by using third-order polynomial 
regression with gestational age at enrolment as predictor variable 
3P-values compare Mean ± SD of two groups. 
5Based on pre-pregnancy values estimated from values at enrolment by using polynomial regression, with gestational 
age at enrolment, gestational age at enrolment squared, and gestational age at enrolment cubed as predictors. 
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SUPPLEMENTAL TABLE 3 
Unadjusted binary anthropometric outcomes of women (n = 1320) who participated in a randomized trial of IFA (pregnancy only), MMN (pregnancy and 











P3 Comparison of 
MMN and IFA4 
Comparison of 
LNS and IFA4 
Comparison of 








           
Inadequate GWG5, % 62.8 (57.4, 67.8) 
[333] 
67.6 (62.5, 72.3) 
[349] 
57.4 (52.0, 62.6) 
[331] 
0.023 1.08  
(0.94, 1.23) 
0.38 0.91  
(0.79, 1.06) 
0.34 0.85  
(0.74, 0.98) 
0.017 
           
Adequate GWG6, % 26.4 (22.0, 31.4) 
[333] 
23.5 (19.3, 28.2) 
[349] 
31.1 (26.4, 36.3) 
[331] 
0.08 0.89  
(0.65, 1.21) 
0.65 1.18  
(0.88, 1.57) 
0.38 1.32  
(0.98, 1.78) 
0.07 
           
Excessive GWG7, % 10.8 ( 7.9, 14.6) 
[333] 
8.9 ( 6.3, 12.4) 
[349] 
11.5 ( 8.5, 15.4) 
[331] 
0.51 0.82  
(0.48, 1.42) 
0.68 1.06  
(0.63, 1.78) 
0.96 1.29  
(0.75, 2.22) 
0.50 
           
GWG <10th centile of expected 
GWG8, % 
29.7 (23.6, 36.5) 
[192] 
27.6 (21.9, 34.1) 
[203] 
23.0 (17.5, 29.6) 
[187] 
0.33 0.93  
(0.64, 1.35) 
0.89 0.77  
(0.51, 1.17) 
0.30 0.83  
(0.55, 1.26) 
0.55 
           
GWW >97th centile of expected 
GWG8, % 
0 0 0 - - - - - - - 
           
Developed overweight or obesity 
by 6 months postpartum9 
18.3 (13.6, 24.3) 
[202] 
18.1 (13.4, 23.9) 
[210] 
17.2 (12.6, 23.0) 
[204] 
0.95 0.99  
(0.60, 1.61) 
1.00 0.94  
(0.57, 1.55) 
0.95 0.95  
(0.58, 1.56) 
0.97 
           
Developed obesity by 6 months 
postpartum10 
0.0 ( 0.0,  100) 
[202] 
0.5 ( 0.1,  3.3) 
[210] 
0.0 ( 0.0,  100) 
[204] 
1.00 - 1.00 1.00  
(0.78, 1.27) 




1GWG, Gestational Weight Gain; IFA, Iron + Folic Acid; LNS, Small Quantity Lipid-based Nutrient Supplement (SQ-LNS); MMN, Multiple Micronutrients. 
IFA group: women received 60 mg Fe + 400 mg folic acid/d during pregnancy, and placebo (200 mg Ca/d) during the first 6 mo postpartum; MMN group: 
women received 18 vitamins and minerals (including 20 mg Fe)/d during pregnancy and the first 6 mo postpartum; LNS group: women received 20 g/d LNS with 
the same micronutrients as the MMN group + Ca, P, K, and Mg as well as macronutrients during pregnancy and the first 6 mo postpartum Results are based 
Logistic Regression (SAS PROC GLIMMIX).  
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2Values are percentages (95% CI) [n]. Percentages (95% CIs) are based on pre-pregnancy values estimated from those measured at enrolment, by using third-
order polynomial regression with gestational age at enrolment as predictor variable. 
3P-value compares all 3groups, with Tukey-Kramer adjustment for pairwise comparisons. 
4Relative Risks, RR (95% CI) and their P-values are based on Poisson regression (1) 
5Below (<) the lower cut-off of Institute of Medicine (IOM)’s recommended range (2). 
6Within the IOM’s recommended range (2). 
7Above (>) the upper cut-off of Institute of Medicine (IOM)’s recommended range (2). 
8Based on INTERGROWTH-21st Standards for women whose estimated pre-pregnancy weight was normal (BMI 18.50-24.99). The 3rd centile of expected GWG 
was calculated as exp((1.382972 - 56.14743 * GA**-2 + 0.2787683 * GA **0.5) + (-1.88 * (0.2501993731 + 142.4297879 * GA **-2 - 61.45345 * GA **-2 * 
log(GA)))) - 8.75,0.1), where GA = weeks of gestational at the last antenatal measurement (3). The 97th centile of expected GWG was calculated by replacing the 
-1.88 in the formula for the 3rd centile of expected GWG by 1.88 (3). No woman in the entire sample had total GWG above the 97th centile of the expected GWG 
based on the INTERGROWTH-21st Standards. 
9Proportion of women with normal BMI pre-pregnancy who became overweight or obese by 6 mo postpartum.  
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SUPPLEMENTAL TABLE 4   
Unadjusted binary anthropometric outcomes of women (n=1320) who participated in randomized trial of daily IFA 
(pregnancy only), MMN (pregnancy + lactation) and SQ-LNS (pregnancy + lactation) supplementation in a semi-





P Relative Risk 
 (95% CI)3 
Inadequate GWG4, % 65.2 (61.6, 68.7) [682] 57.4 (52.0, 62.6) [331] 0.016 0.9 (0.79, 0.98) 
     
Adequate GWG5, % 24.9 (21.8, 28.3) [682] 31.1 (26.4, 36.3) [331] 0.038 1.3 (1.02, 1.54) 
     
Excessive GWG6, % 9.8 (7.8, 12.3) [682] 11.5 (8.5, 15.4) [331] 0.42 1.2 (0.80, 1.70) 
     
GWG <10th centile of expected GWG7, 
% 
28.6 (24.4, 33.3) [395] 23.0 (17.5, 29.6) [187] 0.15 0.80 (0.59, 1.09) 
     
GWW >97th centile of expected 
GWG7, % 
0 0 - - 
     
Developed overweight or obesity by 6 
months postpartum8 
18.2 (14.8, 22.2) [412] 17.2 (12.6, 23.0) [204] 0.75 0.94 (0.65, 1.36) 
     
Developed obesity by 6 months 
postpartum9 
0.2 (0.0, 1.7) [412] 0.0 (0.0, 100) [204] 0.98 0.0 (0.00, 0.00) 
 
1GWG, Gestational weight gain; IFA, Iron + folic acid; LNS, Lipid-based nutrient supplement; MMN, Multiple 
micronutrients; SQ-LNS, Small quantity lipid-based nutrient supplement; IFA+MMN = IFA and MMN groups 
combined: women were intended to receive 60 mg iron + 400 µg folic acid during pregnancy and placebo during the 
first 6 mo postpartum, or  a multiple micronutrient capsule containing 18 vitamins and minerals (including 20 mg 
iron) during pregnancy and the first 6 mo postpartum; LNS group: women received SQ-LNS-for-women with the 
same micronutrients as the multiple micronutrients, plus 4 more minerals (Ca, P, K and Mg) as well as 
macronutrients during pregnancy and the first 6 mo postpartum. All supplements were intended for daily 
consumption. Results are based Logistic Regression models (SAS PROC GLIMMIX). 
2Values are percentages (95% CI) [n]. Percentages (95% CIs) are based on pre-pregnancy values estimated from 
those measured at enrolment, by using third-order polynomial regression with gestational age at enrolment as 
predictor variable. 
3Relative risks and 95% CIs were calculated by using Poisson regression (1) 
4Below (<) the lower cut-off of Institute of Medicine (IOM)’s recommended range (2). 
5Within the IOM’s recommended range (2). 
6Above (>) the upper cut-off of Institute of Medicine (IOM)’s recommended range (2). 
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7Based on INTERGROWTH-21st Standards for women whose estimated pre-pregnancy weight was normal (BMI 
18.50-24.99). The 3rd centile of expected GWG was calculated as exp((1.382972 - 56.14743 * GA**-2 + 0.2787683 
* GA **0.5) + (-1.88 * (0.2501993731 + 142.4297879 * GA **-2 - 61.45345 * GA **-2 * log(GA)))) - 8.75,0.1), 
where GA = weeks of gestational at the last antenatal measurement (3). The 97th centile of expected GWG was 
calculated by replacing the -1.88 in the formula for the 3rd centile of expected GWG by 1.88 (3). No woman in the 
entire sample had total GWG above the 97th centile of the expected GWG based on the INTERGROWTH-21st 
Standards. 
8Proportion of women with normal BMI pre-pregnancy who became overweight or obese by 6 mo postpartum.  
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